Addressing Generic-Drug Market Failures — The Case for Establishing a Nonprofit Manufacturer

New England Journal of Medicine

Volumn 378, Issue 20, 2018, Pages 1857-1859

  Liljenquist, Dan ^a   Bai, Ge ^b   Anderson, Gerard F ^c  

^a INTERMOUNTAIN HEALTHCARE   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOSIMILAR AGENT; GENERIC DRUG; PYRIMETHAMINE; TRIENTINE;

CAPITAL; COMPETITION; DRUG APPROVAL; DRUG COST; DRUG INDUSTRY; DRUG MARKETING; FOOD AND DRUG ADMINISTRATION; HEALTH CARE ACCESS; HUMAN; INVESTMENT; PHARMACY; PRIORITY JOURNAL; PROFIT; REVIEW; TOXOPLASMOSIS; WILSON DISEASE; ECONOMIC ASPECT; ECONOMICS; NON PROFIT ORGANIZATION; UNITED STATES;

DRUG COSTS; DRUG INDUSTRY; DRUGS, GENERIC; ECONOMIC COMPETITION; HUMANS; ORGANIZATIONS, NONPROFIT; UNITED STATES;

EID: 85047328085     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMp1800861     Document Type: Review

References (5)

1. Alpern JD, Stauffer WM, Kesselheim AS. High-cost generic drugs — implications for patients and policymakers. N Engl J Med 2014;371:1859-62.
2. Fox ER, Sweet BV, Jensen V. Drug shortages: a complex health care crisis. Mayo Clin Proc 2014;89:361-73.
3. Greene JA, Anderson G, Sharfstein JM. Role of the FDA in affordability of off-patent pharmaceuticals. JAMA 2016;315:461-2.
4. Karas L, Shermock KM, Proctor C, Socal M, Anderson GF. Limited distribution networks stifle competition in the generic and biosimilar drug industries. Am J Manag Care 2018;24(4):e122-e127.
5. Generic drug user fee amendments. Silver Spring, MD: Food and Drug Administration, 2018 (https://www.fda.gov/ForIndustry/UserFees/GenericDrugUserFees/default .htm).